ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 164 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2016. The put-call ratio across all filers is 1.24 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $52,798 | -23.4% | 1,481 | -0.9% | 0.01% | -10.0% |
| Q2 2023 | $68,918 | +15.0% | 1,494 | 0.0% | 0.01% | +11.1% |
| Q1 2023 | $59,909 | +85484.3% | 1,494 | -1.2% | 0.01% | -18.2% |
| Q4 2022 | $70 | -99.9% | 1,512 | 0.0% | 0.01% | +10.0% |
| Q3 2022 | $63,000 | -30.0% | 1,512 | 0.0% | 0.01% | -33.3% |
| Q2 2022 | $90,000 | -53.8% | 1,512 | -43.6% | 0.02% | -37.5% |
| Q1 2022 | $195,000 | -0.5% | 2,682 | +14.9% | 0.02% | +9.1% |
| Q4 2021 | $196,000 | -19.3% | 2,334 | -13.5% | 0.02% | -26.7% |
| Q3 2021 | $243,000 | -5.4% | 2,699 | 0.0% | 0.03% | 0.0% |
| Q2 2021 | $257,000 | -18.9% | 2,699 | -3.2% | 0.03% | -23.1% |
| Q1 2021 | $317,000 | -4.2% | 2,788 | +16.5% | 0.04% | -4.9% |
| Q4 2020 | $331,000 | +68.0% | 2,393 | 0.0% | 0.04% | +46.4% |
| Q3 2020 | $197,000 | -58.6% | 2,393 | -68.1% | 0.03% | -65.9% |
| Q1 2016 | $476,000 | – | 7,512 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 213,887 | $29,608,000 | 2.19% |
| Rock Springs Capital Management LP | 566,500 | $78,421,000 | 1.66% |
| FEDERATED HERMES, INC. | 4,280,528 | $592,554,000 | 1.21% |
| AtonRa Partners | 17,646 | $2,443,000 | 1.20% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 218,390 | $30,232,000 | 1.05% |
| EMERALD ADVISERS, LLC | 226,875 | $31,406,000 | 1.04% |
| Atika Capital Management LLC | 89,000 | $12,319,000 | 0.96% |
| Capital Impact Advisors, LLC | 25,582 | $3,541,000 | 0.87% |
| JGP Global Gestao de Recursos Ltda. | 1,586 | $220,000 | 0.83% |
| CAPITAL INTERNATIONAL LTD /CA/ | 79,742 | $11,039,000 | 0.64% |